Patent application number | Description | Published |
20090054336 | Binding Agent - Agents which bind to cell surface receptors; methods to manufacture such agents; therapeutic compositions comprising such agents; and screening methods to identify novel agents. | 02-26-2009 |
20090221477 | Linkers - We disclose therapeutic polypeptides comprising at least two domains capable of binding to a cytokine receptor, wherein the domains are connected by a peptide linker, wherein the linker optionally comprises a rigid alpha helical region. | 09-03-2009 |
20090239801 | Modified Fusion Polypeptides - Chimeric polypeptides wherein the polypeptides comprise a modified binding domain of growth hormone linked to a receptor binding domain of growth hormone receptor; and tandems/oligomers of such modified growth hormone binding domains. | 09-24-2009 |
20090270325 | GROWTH FACTOR - We describe a chimeric protein comprising a growth hormone polypeptide linked to a polypeptide comprising the extracellular binding domain of growth hormone receptor; its use in enhancing the growth and metabolism of non-human animals and homodimers comprising said chimeric protein. | 10-29-2009 |
20100035804 | POLYPEPTIDE ANTAGONIST - We describe a circularly permuted growth hormone polypeptide antagonist; compositions comprising said antagonist and methods to treat conditions that would benefit from administration of said antagonist. | 02-11-2010 |
20100197582 | GROWTH HORMONE FUSION PROTEINS - We disclose growth hormone fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone deficiency that use said proteins. | 08-05-2010 |
20100197589 | MODIFIED GROWTH HORMONE POLYPEPTIDES - We describe modified growth hormone fusion proteins and dimers comprising said fusion proteins; nucleic acid molecules encoding said proteins and methods of treatment that use said proteins in the treatment of conditions that result from growth hormone excess. | 08-05-2010 |
20100316604 | INTERFERON LAMBDA FUSION POLYPEPTIDES - The disclosure relates to interferon lambda fusion polypeptides and dimers; nucleic acid molecules encoding said polypeptides and/or dimers, vectors and transformed cells including such nucleic acid molecules, pharmaceutical compositions including the interferon lambda fusion polypeptides and/or dimers, and methods of treating a disorder in a human subject by administering the polypeptides and/or dimers. | 12-16-2010 |
20110008283 | INTERFERON FUSION PROTEINS - The disclosure relates to interferon fusion polypeptides and dimers; nucleic acid molecules encoding said polypeptides and methods of treatment that use said polypeptides/dimers. | 01-13-2011 |
20110039775 | THYROID STIMULATING HORMONE FUSION PROTEINS - We disclose TSH fusion proteins comprising TSHα and/or TSH β and methods to treat diseases that would benefit from administration of TSH agonists and antagonists. | 02-17-2011 |
20110092417 | LEPTIN FUSION PROTEINS - The disclosure relates to leptin fusion polypeptides; nucleic acid molecules encoding said polypeptides and methods of treatment that use said polypeptides. | 04-21-2011 |
20110152187 | INSULIN-LIKE GROWTH FACTOR FUSION PROTEINS - This disclosure relates to insulin-like growth factor fusion polypeptides; nucleic acid molecules encoding said polypeptides and methods of treatment that use said polypeptides. | 06-23-2011 |
20110172165 | MODIFIED LINKERS - We describe modified peptide linkers that function to link at least first and second polypeptides wherein said modified peptide linker comprises a motif for the addition of a sugar moiety. | 07-14-2011 |
20110182848 | GRANULOCYTE COLONY STIMULATING FACTOR - We disclose granulocyte colony stimulating factor fusion polypeptides; nucleic acid molecules encoding said polypeptides and methods of treatment that use said proteins. | 07-28-2011 |
20110230401 | INSULIN FUSION POLYPEPTIDES - We disclose insulin fusion polypeptides and dimers; nucleic acid molecules encoding said polypeptides and methods of treatment that use said polypeptides/dimers. | 09-22-2011 |
20110245174 | GLP-1 FUSION POLYPEPTIDES - We describe nucleic acid molecules that encode fusion polypeptides comprising GLP-1, or a receptor binding part thereof, linked directly or indirectly to a polypeptide that naturally binds GLP-1. | 10-06-2011 |
20110275564 | ERYTHROPOIETIN - This disclosure relates to erythropoietin (EPO) fusion polypeptides; nucleic acid molecules encoding said polypeptides and methods of treatment that use said polypeptides. | 11-10-2011 |
20120322735 | MODIFIED GROWTH HORMONE POLYPEPTIDES - We describe modified growth hormone fusion proteins and dimers comprising said fusion proteins; nucleic acid molecules encoding said proteins and methods of treatment that use said proteins in the treatment of conditions that result from growth hormone excess. | 12-20-2012 |
20130023477 | GROWTH HORMONE FUSION PROTEINS - We disclose growth hormone [GH] fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone deficiency that use said fusion proteins. The GH fusion proteins comprise human GH covalently linked to the extracellular domain of Growth Hormone Receptor [GHR] either as a direct in-frame translational fusion or via a flexible peptide linker. The GH/GHR fusion proteins have exceptional pharmacokinetics and are potent growth hormone receptor agonists. The GH/GHR fusion proteins form head to tail dimers. | 01-24-2013 |
20140336117 | MODIFIED RECEPTOR FUSION PROTEINS - We disclose growth hormone fusion proteins that have increased in vivo stability and activity; nucleic acid molecules encoding said proteins and methods of treatment of growth hormone related diseases that would benefit from growth hormone agonists or antagonists. | 11-13-2014 |